[BioS] Inventera launches joint research with UCSF on Nano scaffold ADC
Predicted impact: Low
Joint research with UCSF; early-stage collaboration with no stated revenue size.
Inventera인벤테라
0007J0 · KOSDAQ · ₩0007J0 · 인벤테라
₩8,830▲ ₩200 (2.32%)End-of-day · Oct 28, 2026 · End-of-day prices.
G2GBIO Hits Limit-Up on China Partnership; Inventera Gains on U.S. Clinical Trial Clearance [K-Bio...
Predicted impact: Low
US Phase 1 trial approval already reported in the past 14 days; small company with no revenue.
G2GBIO Surges on Chinese Pharma Tie-Up; Inventera Gets Positive Signal on U.S. Trial [Bio Market Briefing]
Predicted impact: Low
China platform evaluation partnership already reported in the past 14 days; undisclosed value.
Inventera to file for approval of MRI contrast agent for musculoskeletal imaging in Q4, targeting a turn to profit in 2028
Predicted impact: Medium
Planned Q4 approval filing and 2028 profit target for pre-revenue company; timeline far off.
Inventerra receives US Phase 1 clinical trial approval for oral contrast agent for pancreaticobiliary imaging
Predicted impact: Low
US Phase 1 trial approval for an early-stage agent; no revenue and small market value.
Also known as: Inventera / 인벤테라 / 0007J0 / KRX:0007J0
Source: KRX statistical information